Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

532
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
532
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

734
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
734
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

1.4K
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.4K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

681
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
681
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.1K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inflammation rewires the enteric nervous system through neurogenic monocyte recruitment.

The Journal of experimental medicine·2026
Same author

Development of a targeted oral pharmacologic duodenal exclusion therapy for the treatment of metabolic diseases.

Science advances·2025
Same author

Age-associated changes in lineage composition of the enteric nervous system regulate gut health and disease.

eLife·2023
Same author

Miniaturized Capsule System Toward Real-Time Electrochemical Detection of H<sub>2</sub> S in the Gastrointestinal Tract.

Advanced healthcare materials·2023
Same author

Effects of Psychology and Extragastrointestinal Symptoms on Health Care Use by Subjects With and Without Irritable Bowel Syndrome.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2019
Same author

Response to Zidar et al.

The American journal of gastroenterology·2019
Same journal

Sparganosis.

The New England journal of medicine·2026
Same journal

Caring for an Aging America - The Looming Crisis of the Long-Term-Care Workforce.

The New England journal of medicine·2026
Same journal

For Those Left Behind.

The New England journal of medicine·2026
Same journal

Colliding Forces - The Aging of the Baby Boom Generation and Contracting Nursing-Home Supply.

The New England journal of medicine·2026
Same journal

Mandated State-Level Surveillance of Assisted Reproductive Technology - An Emerging Threat in the United States.

The New England journal of medicine·2026
Same journal

Ebola at 50 - Lessons for Outbreak Response and Preparedness.

The New England journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.0K

Functional Dyspepsia.

Pankaj J Pasricha1, Nicholas J Talley2

  • 1Mayo Clinic, Scottsdale, AZ.

The New England Journal of Medicine
|January 7, 2026
PubMed
Summary
This summary is machine-generated.

Functional dyspepsia is a serious condition causing weight loss and food aversion. Identifying subgroups, like those with Th2 inflammation, is key for better treatment strategies.

More Related Videos

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.2K
Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

1.1K

Related Experiment Videos

Last Updated: Jan 13, 2026

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

7.0K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.2K
Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis
05:36

Herbs-Partitioned Moxibustion on the Navel in a Rat Model of Primary Dysmenorrhea with Cold Coagulation and Blood Stasis

Published on: October 4, 2024

1.1K

Area of Science:

  • Gastroenterology
  • Immunology

Background:

  • Functional dyspepsia (FD) is a prevalent gastrointestinal disorder with significant morbidity, including weight loss and food aversion.
  • FD likely encompasses heterogeneous conditions, complicating diagnosis and treatment.
  • A subset of FD patients may exhibit local mucosal microinflammation linked to a T-helper 2 (Th2) immune response.

Purpose of the Study:

  • To explore the potential role of aberrant Th2 responses in a subgroup of functional dyspepsia patients.
  • To investigate the overlap between functional dyspepsia, irritable bowel syndrome, and gastroesophageal reflux disease.
  • To highlight the current empirical treatment approaches for functional dyspepsia.

Main Methods:

  • Review of existing literature on functional dyspepsia pathophysiology and clinical presentation.
  • Analysis of patient subgroups based on immune responses and overlapping gastrointestinal syndromes.
  • Examination of current therapeutic strategies, including pharmacologic and non-pharmacologic interventions.

Main Results:

  • Patients with functional dyspepsia may represent a distinct subgroup characterized by local mucosal microinflammation and Th2 immune responses.
  • Significant symptom overlap exists between functional dyspepsia, irritable bowel syndrome, and gastroesophageal reflux disease, with combined conditions leading to increased severity.
  • No specific drug is approved for functional dyspepsia, necessitating empirical symptom-directed management.

Conclusions:

  • Aberrant Th2 responses may identify an important subgroup of functional dyspepsia patients.
  • Understanding the overlap with other functional gastrointestinal disorders is crucial for managing severe cases.
  • Current treatment for functional dyspepsia is empirical, focusing on symptom relief through acid suppressants, neuromodulators, nutritional, and psychological support.